Financial Data and Key Metrics Changes - Revenue for the full year 2024 reached a record $2.519 billion, representing a growth of $951 million or 61% compared to the prior year [7][32] - Non-GAAP EPS was a record $3.04, increasing by 31% despite a 20% increase in diluted shares [8][32] - Free cash flow for the full year was an all-time high of $405 million, up $240 million or 145% year-over-year [8][32] - Q4 revenue was $657 million, growing 7% year-over-year [11][33] - Q4 non-GAAP EPS was $0.84, an increase of 40% compared to the prior year [11][34] - Q4 free cash flow was $193 million, up 136% year-over-year [12][35] Business Line Data and Key Metrics Changes - U.S. Spine grew 4% in Q4, driven by strong performance in expandables, MIS screws, cervical offerings, and 3D printed spacers [13] - Enabling Technologies revenue for Q4 was $47 million, growing 44% year-over-year [19][36] - Musculoskeletal sales for Q4 were $610.3 million, growing 4.5% compared to the prior year [35] - International revenue for Q4 was $135.4 million, growing 7.7% as reported and 8.9% on a constant currency basis [37] Market Data and Key Metrics Changes - The primary countries driving international growth included Japan, the United Kingdom, Italy, and Ireland, with high double-digit growth in most markets [23] - The combined trauma and NSO business delivered 8% growth in Q4, driven by strong performance in the base trauma business [24] Company Strategy and Development Direction - The company plans to return to a debt-free status by Q1 2025, paying off the remainder of the $1 billion debt from the NuVasive merger [9] - The acquisition of Nevro Corporation for approximately $250 million is expected to expand the company's reach into the musculoskeletal market [26] - The company aims to achieve $170 million in synergies over three years from the NuVasive merger, with 55% realized in the first year [51] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the integration of Nevro and its potential to enhance the company's product offerings and market reach [26][28] - The company anticipates 2025 revenue guidance of $2.66 billion to $2.69 billion, with non-GAAP EPS ranging from $3.40 to $3.50 [53] - Management remains focused on innovation and operational integration to drive growth in 2025 and beyond [55][56] Other Important Information - The company launched 18 new products in 2024, with five new products launched in Q4 alone [10][12] - The company expects to achieve adjusted gross margins in the range of 67.5% to 68.5% in 2025, with a long-term goal of mid-70s adjusted gross profit [41] Q&A Session Summary Question: Why was this the right time to enter the SCS market and why Nevro? - Management highlighted the integration depth achieved with NuVasive, allowing the company to capitalize on the Nevro opportunity, which is seen as a well-rounded asset for future development [60] Question: Do you expect to benefit from competitors selling their spinal implant businesses? - Management indicated that while market activity is significant, the company will remain focused on its long-term strategy and innovation, rather than immediate market disruptions [64] Question: How does the Nevro acquisition compare to other investment programs? - Management stated that the Nevro acquisition would not significantly shift investment levels and would be integrated into existing capital expenditure plans [69][71] Question: What is the expected gross margin cadence for 2025? - Management expects modest improvement in gross margins throughout 2025, with more significant expansion anticipated in 2026 as in-sourcing efforts take effect [85] Question: What are the growth prospects for the spine market in 2025? - Management anticipates the spine market will trend around 3% growth historically, with the company aiming to outpace this through innovation and investment [136]

For the quarter ended December 2024, Globus Medical (GMED) reported revenue of $657.29 million, up 6.6% over the same period last year. EPS came in at $0.84, compared to $0.60 in the year-ago quarter.The reported revenue represents a surprise of +2.02% over the Zacks Consensus Estimate of $644.28 million. With the consensus EPS estimate being $0.76, the EPS surprise was +10.53%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall St ...

Core Insights - Globus Medical reported quarterly earnings of $0.84 per share, exceeding the Zacks Consensus Estimate of $0.76 per share, and showing an increase from $0.60 per share a year ago, resulting in an earnings surprise of 10.53% [1] - The company achieved revenues of $657.29 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 2.02% and up from $616.53 million year-over-year [2] - The stock has underperformed the market with a gain of about 1.7% since the beginning of the year, compared to the S&P 500's gain of 4.5% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.79 on revenues of $647.24 million, and for the current fiscal year, it is $3.47 on revenues of $2.67 billion [7] - The estimate revisions trend for Globus Medical is mixed, leading to a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Medical - Instruments industry, to which Globus Medical belongs, is currently in the top 34% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8] - Another company in the same industry, OrthoPediatrics, is expected to report a quarterly loss of $0.22 per share, with revenues projected at $52.7 million, reflecting a 40.1% increase year-over-year [9][10]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to _______________ Title of each class Trading Symbol(s) Name of exchange on which registered Class A Common Stock, par value $.001 per share GMED New York Stock E ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2025 GLOBUS MEDICAL, INC. (Exact name of registrant as specified in charter) DELAWARE 001-35621 04-3744954 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 2560 GENERAL ARMISTEAD AVENUE, AUDUBON, PA 19403-5214 (Address of princ ...

AUDUBON, Pa., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced its financial results for the fourth quarter and year ended December 31, 2024. Fourth Quarter 2024: Worldwide net sales were $657.3 million, an increase of 6.6% on an as-reported basis and an increase of 6.9% on a constant currency basisGAAP net income for the quarter was $26.5 millionGAAP diluted earnings per share (“EPS”) was $0.19 and non-GAAP diluted EPS was $0 ...

AUDUBON, Pa. and REDWOOD CITY, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Globus Medical (NYSE:GMED), a leading musculoskeletal solutions company, and Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced they have entered into a definitive agreement for Globus Medical to acquire all shares of Nevro in an all-cash transaction. Under the terms of the agreement, which was unanimously approved by the ...

AUDUBON, Pa. and REDWOOD CITY, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Globus Medical (NYSE: GMED), a leading musculoskeletal solutions company, and Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced they have entered into a definitive agreement for Globus Medical to acquire all shares of Nevro in an all-cash transaction. Under the terms of the agreement, which was unanimously approved by th ...

AUDUBON, Pa., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its financial results for the fourth quarter and full-year ended December 31, 2024 after the market close on Thursday, February 20, 2025. A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com. Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment community ...

If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Globus Medical (GMED) . This company, which is in the Zacks Medical - Instruments industry, shows potential for another earnings beat.This medical device company has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise for the last two quarters was 18.99%.F ...